Startups welcome legendary board members aboard

DiNAQor – three prominent cardiovascular industry and Academic Experts
Louis G. Lange, Steven Zelenkofske, and Silke Rickert-Sperling, some of the most renowned cardiovascular industry and academic experts are joining the board of directors of DiNAQor, a genetic medicine platform company focused on advancing novel solutions for patients suffering from severe, inherited forms of heart disease. with these appointments, the startup has the startup is now set to reach the next goals. Louis Lange is an industry pioneer, with an inspiring career as a biotech entrepreneur and leader; Steve Zelenkofske has an exceptional track-record of clinical development and regulatory approval successes, and Silke Rickert-Sperling is a visionary researcher in cardiovascular genetics. All three of these leaders will provide invaluable counsel and support to DiNAQOR as we embark on a phase of rapid expansion to develop novel genetic treatments for the failing heart

Memo Therapeutics – chairman of the board and a board member
Memo Therapeutics, an innovator in the field of antibody discovery and development, appointed Elias Papatheodorou as Chairman of the Board of Directors and Thomas Taapken as a Member of the Board of Directors. Papatheodorou has over 20 years of C-level experience in all aspects of pharmaceutical commercialization, including sales & marketing, business development, M&A, and operations. He has a proven track-record of managing clinical-stage organizations and preparing them for sale. He is currently the CEO of Genkyotex, which was sold to Calliditas Therapeutics, and was previously the CBO at Covagen, which was acquired by Janssen Pharmaceuticals.
Thomas Taapken has also 20 years of experience in the life science industry at the executive management level. His experience spans public & private financings, IPO, corporate & business development, and research. He is currently the CFO of InflaRx and has previously held various C-level positions at both private and publicly listed companies, including Medigene, Epigenomics and Biotie Therapies. He holds a PhD in Organic Chemistry from Technical University of Berlin.

Urban Connect - Europe's most thoughtful and transformative climate pioneers
Renat Heuberger, founder and CEO of South Pole, one of the world's biggest and earliest carbon finance groups has joined the board of directors of Urban Connect, a multimodal sustainable mobility platform for companies that offers companies an ecosystem of low-emission, shared vehicles. Renat's pioneering experience and insight into growing large sustainability-driven businesses will be key in helping Urban Connect chart the next phase of growth and business model innovation by supporting the startup on its journey to bring more climate neutral, multi-modal mobility options to even more corporate clients.

Inyova Impact Investing – Alois Flatz
Alois Flatz, a sustainable finance pioneer and a renowned company builder has joined the board at Inyova Impact Investing to support the company on its growth journey. He had already invested in Inyova as a venture capitalist in 2018 and was a member of the advisory board. Flatz worked with Al Gore at Generation Investment Management, one of the earliest and largest sustainable investing funds, launched the S&P Dow Jones Indices Sustainability Index (DJSI) and co-founded successful technology and sustainability companies such as meepl ⎜ Fision AG (acquired by Zalando) and Forma Futura Invest AG.

Asceneuron – Catherine Moukheibir joins the board
Based in Lausanne Asceneuron is a clinical-stage company dedicated to targeting the root cause of neurodegenerative diseases. The startup recently welcomed Catherine Moukheibir to its Board of Directors. Catherine is a highly respected healthcare executive with extensive experience over the last 30 years of leadership in finance, capital markets and life sciences. She has previously worked as a Chairman, Non-Executive Director and Chief Executive Officer in the biotech and pharmaceutical sectors, successfully raising private and public capital as well as overseeing several major licensing deals and acquisitions.

(Press release/RAN)
Photo L-R: L-R: Silke Rickert-Sperling, Elias Papatheodorou & Thomas Taapken, Renat Heuberger, Alois Flatz & Catherine Moukheibir